Amgen psoriasis candidate bests J&J's Stelara; FDA slams Sciecure insomnia drug sales materials;

> Amgen's ($AMGN) psoriasis drug brodalumab beat Johnson & Johnson's ($JNJ) Stelara at clearing patients' skin in a late-stage study, in the latest round of data for a soon-to-be-upended psoriasis market. Report

> The FDA's pharma marketing police slammed Sciecure Pharma for a lack of fair balance in a sales aid for its insomnia drug Doral. Report

> South Carolina-based Afaxys Pharmaceuticals says its emergency contraceptive, ella, is now available nationwide in the U.S.; the company is particularly focusing on public health providers, urgent centers, ERs and student health centers. Release

> The U.K. drugmaker BTG said it has finally launched its varicose vein treatment Varithena in the U.S., 18 years after it bought the technology. Release

And Finally... Servier is gambling up to $1B on Intarcia's late-stage drug-emitting diabetes device. Report

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Rapper, actress and producer Queen Latifah—whose mother died of sclerosis-associated lung disease—joined Boehringer's "More than Scleroderma” push.